Search results for "fusions"

showing 10 items of 176 documents

The prognosis of patients having received optimal therapy for nonvariceal upper gastrointestinal bleeding might be worse in daily practice than in ra…

2010

International audience; BACKGROUND: Combination of endoscopic haemostatic and high-dose intravenous proton-pump inhibitors is considered to be the standard care for patients with acute peptic ulcer bleeding. AIM: This study assessed predictive factors of rebleeding and death in unselected patients presented to our hospital. METHODS: Consecutive patients with nonmalignant bleeding ulcers and stigmata of recent haemorrhage who received optimal treatment, between 22 August 2003 and 15 October 2007, were studied retrospectively. RESULTS: Among 140 included patients, 45 (32%) rebled and 30 received another haemostatic endoscopy, which was successful in 20 cases. In multivariate analysis, the onl…

MaleMultivariate analysisAdministration Oral2-Pyridinylmethylsulfinylbenzimidazoleslaw.inventionHospitals University0302 clinical medicineRandomized controlled trialRecurrenceRisk FactorslawOdds RatioHospital Mortality030212 general & internal medicineInfusions IntravenousPantoprazoleRandomized Controlled Trials as TopicAged 80 and overMortality rateHemostasis EndoscopicGastroenterologyMiddle AgedCombined Modality TherapyIntensive care unit3. Good healthIntensive Care UnitsPeptic Ulcer HemorrhageTreatment OutcomeInjections IntravenousFemale030211 gastroenterology & hepatologyFranceAdultmedicine.medical_specialtyRisk AssessmentYoung Adult03 medical and health sciencesInternal medicinemedicineHumansAgedRetrospective StudiesChi-Square DistributionHepatologybusiness.industryProton Pump Inhibitors[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyOdds ratiomedicine.disease[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyConfidence intervalSurgeryLogistic ModelsUpper gastrointestinal bleedingRockall scorebusiness
researchProduct

No improvement in perfusion and oxygenation of experimental tumors upon application of vasodilator drugs

2001

The oxygen deficiency seen in solid tumors is predominantly caused by an insufficient O2 supply as a result of inadequate tumor perfusion. The aim of this study was to analyze whether a number of vasodilator drugs might be suitable to increase tumor perfusion and consequently improve the oxygenation status of experimental tumors. Rats with s.c. DS-sarcomas were treated with either Na+-nitroprusside (7-25 microg x min(-1) x kg(-1) BW) or nifedipine (10 microg x min(-1) x kg(-1) BW). Red blood cell (RBC) flux was assessed continuously using laser-Doppler flowmetry and mean tumor pO2 was measured polarographically using O2-sensitive catheter electrodes. Systemic application of the vasodilator …

MaleNitroprussideCancer Researchmedicine.medical_specialtyNifedipineVasodilator AgentsRats Sprague-DawleyNifedipineInternal medicineLaser-Doppler FlowmetrymedicineAnimalsInfusions IntravenousOncogenebusiness.industryOxygenationLaser Doppler velocimetryRatsOxygenRed blood cellmedicine.anatomical_structureEndocrinologyOncologyRegional Blood FlowCardiologyVascular resistanceSarcoma ExperimentalSodium nitroprussidebusinessPerfusionmedicine.drugInternational Journal of Oncology
researchProduct

Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study

2018

Prognostic assessment of patients with hepatocellular carcinoma (HCC) at the time of diagnosis remains controversial and becomes even more complex at the time of restaging when new variables need to be considered. The aim of the current study was to evaluate the prognostic utility of restaging patients before proceeding with additional therapies for HCC. Two independent Italian prospective databases were used to identify 1,196 (training cohort) and 648 (validation cohort) consecutive patients with HCC treated over the same study period (2008-2015) who had complete restaging before decisions about additional therapies. The performance of the Italian Liver Cancer (ITA.LI.CA) prognostic score …

MaleOncologyDatabases FactualLiver cancer; non surgical therapy; prognostic system; surgical therapy; survivalhepatocellular carcinoma stage treatmentKaplan-Meier EstimateCohort StudiesLiver disease0302 clinical medicineMiddle AgedSorafenibPrognosisItaly030220 oncology & carcinogenesisCatheter AblationDisease ProgressionFemale030211 gastroenterology & hepatologysurgical therapyLiver cancerLiver cancermedicine.drugCohort studySorafenibmedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIAClinical Decision-MakingRisk AssessmentsurvivalDisease-Free SurvivalStatistics Nonparametric03 medical and health sciencesnon surgical therapyInternal medicinemedicineHepatectomyHumansInfusions Intra-ArterialNeoplasm InvasivenessSurvival analysisAgedNeoplasm StagingRetrospective StudiesAnalysis of VarianceHepatologybusiness.industryprognostic systemReproducibility of ResultsCancerRetrospective cohort studymedicine.diseaseSurvival AnalysisbusinessProgressive disease
researchProduct

Phase 2 Trial of the Continuous IV Administration of Interferon-? in Patients With Disseminated Malignant Melanoma

2006

BACKGROUND Interferons have been reported to significantly contribute to tumor suppression via both induction of p53 gene expression and inhibition of angiogenesis. OBJECTIVE The assessment of treatment toxicity and antitumoral effectiveness of continuous IV administration of interferon-beta based on an overall evaluation of laboratory, radiographic, and clinical parameters observed during the trial. METHODS The authors treated patients with advanced malignant melanoma with continuous IV infusions of 1 x 10(6) IU interferon-beta daily ( approximately 0.6 x 10(6) IU interferon-beta/m2 daily). RESULTS Continuous IV administration of interferon-beta had no significant effect on overall patient…

MaleOncologymedicine.medical_specialtySkin NeoplasmsAngiogenesisAntineoplastic AgentsDrug Administration ScheduleInterferonInternal medicinemedicineHumansIn patientNeoplasm MetastasisInfusions IntravenousMelanomaAgedInterferon betabusiness.industryMelanomaInterferon-betaGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyDiscontinuationSurgeryTreatment OutcomeToxicityFemalebusinessmedicine.drugSKINmed
researchProduct

Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity

2017

Background Continuous infusion of doxorubicin has been a strategy to reduce cardiotoxicity. Epirubicin is another anthracycline in common clinical use. However, evidence is lacking regarding whether this strategy can reduce cardiotoxicity of epirubicin without compromising antineoplastic efficacy. Design and methods Healthy rats were randomized into groups: epirubicin (8 mg/kg) delivered intraperitoneally via micro osmotic pumps (MOP), epirubicin (8 mg/kg) by intraperitoneal (IP) bolus injection, and placebo control. Blood samples were collected for analyzing biomarkers of myocardial injury and pharmacokinetics. At chosen times, sub-groups of animals were sacrificed for histopathology. A mo…

MalePhysiologyCancer Treatmentlcsh:Medicine030204 cardiovascular system & hematologyPharmacologyBiochemistryRats Sprague-DawleyMice0302 clinical medicineBolus (medicine)Intraperitoneal InjectionsBreast TumorsMedicine and Health Scienceslcsh:Scienceskin and connective tissue diseasesInfusions IntravenousRoutes of AdministrationMultidisciplinaryAntibiotics AntineoplasticArea under the curveHeartAnimal ModelsBody FluidsBloodExperimental Organism SystemsOncology030220 oncology & carcinogenesisAnatomyEpirubicinmedicine.drugResearch ArticleAnthracyclineMouse ModelsResearch and Analysis MethodsBlood Plasma03 medical and health sciencesModel OrganismsPharmacokineticsIn vivoCell Line TumorBreast CancermedicineAnimalsDoxorubicinPharmacokineticsAnimal Models of DiseaseEpirubicinPharmacologyCardiotoxicitybusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesRatsAnimal Studieslcsh:QbusinessBiomarkersPLoS ONE
researchProduct

Effects of hypertonic/hyperoncotic treatment after rat cortical vein occlusion*

2003

Objective To examine the effects of hypertonic/hyperoncotic treatment on physiologic variables and regional cerebral blood flow and to test its neuroprotective efficiency in a model of permanent venous ischemia. Design Randomized prospective study. Setting University research institute. Subjects Adult male Wistar rats, weighing 359 +/- 54 g (n = 38). Interventions Rats were subjected to photochemical occlusion of two adjacent cortical veins. A randomized infusion with vehicle (0.9% NaCl), 10% hydroxyethyl starch 200,000 (HES), or 7.5% saline plus 10% hydroxyethyl starch 200,000 (HHES) was started 30 mins after two-vein occlusion. Effects on physiologic variables and regional cerebral blood …

MalePlasma SubstitutesIschemiaHemodynamicsHydroxyethyl starchCritical Care and Intensive Care MedicineBrain IschemiaHydroxyethyl Starch DerivativesIntensive careOcclusionmedicineAnimalsRats WistarInfusions IntravenousSaline Solution Hypertonicbusiness.industryOsmolar ConcentrationHemodynamicsLaser Doppler velocimetrymedicine.diseaseRatsHypotonic SolutionsCerebral blood flowCerebrovascular CirculationAnesthesiabusinessPerfusionmedicine.drugCritical Care Medicine
researchProduct

Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwentsurgical reperfusion: a randomized double-…

2007

Background: The inflammatory cascade has been hypothesized to be an important mechanism of post-ischaemic myocardial reperfusion injury and several studies demonstrated that C1 esterase inhibitor (C1 -INH) is effective in post-ischaemia myocardial protection. Therefore, we aimed to investigate prospectively in a randomised double-blind study the cardioprotective effects of C1-INH in ST segment elevation myocardial infarction (STEMI) in patients who underwent emergent reperfusion with coronary artery bypass grafting (CABG). Methods: In this study, we enrolled 80 patients affected with STEMI who underwent emergent CABG. Patients were assigned in two groups (C1-INH group: receive 1000 Ul of C1…

MalePulmonary and Respiratory MedicineCardiac function curvemedicine.medical_specialtyMean arterial pressureCardiotonic AgentsMyocardial InfarctionCardiac indexMyocardial ReperfusionComplement C1 Inactivator ProteinsCoronary artery bypass surgeryReperfusion therapyDouble-Blind MethodInternal medicinemedicineHumansProspective StudiesMyocardial infarctionCoronary Artery BypassInfusions IntravenousSTEMI patients CABG C1 esterase inhibitor Reperfusion injury Complement cascade Myocardial function recoverybusiness.industryST elevationTroponin IComplement C4aGeneral MedicineMiddle Agedmedicine.diseaseMyocardial ContractionComplement Inactivating AgentsTreatment OutcomeComplement C3aCardiologyFemaleSurgeryCardiology and Cardiovascular MedicinebusinessReperfusion injury
researchProduct

Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1.

2009

Purpose. To evaluate the therapeutic effects of L-propionyl-carnitine (LPC) in patients with critical limb ischemia (CLI), as defined by the TASC guidelines. Methods. The study, double-blinded, randomised, assessed intravenous infusion of LPC 1.2 g/day in combination with PGE-1, 60 mg/day (LPC group: 37 patients), or PGE-1 only (control group: 38 patients) in a total of 75 patients suffering from CLI. Treatment duration was 20 days. We evaluated rest pain, maximum walking distance (MWD) and skin ulcer size. Results. In both groups we observed a significant reduction in pain score and ulcer size and an increase in MWD. In the patients treated with the combination, the improvement was greater…

MaleSettore MED/09 - Medicina InternaCardiotonic AgentsVasodilator AgentsProstaglandin E1IschemiaPainWalkinglaw.inventionchemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawIschemiaCarnitinemedicineHumansPharmacology (medical)CarnitineAlprostadilProstaglandin E1Infusions IntravenousAgedPharmacologyLegCritical Limb Ischemiabusiness.industryTherapeutic effectLeg UlcerDrug SynergismGeneral MedicineCritical limb ischemiaL-PropionylcarnitineSkin ulcerMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareTreatment OutcomechemistryAnesthesiaChronic Diseaselipids (amino acids peptides and proteins)Drug Therapy CombinationFemalemedicine.symptomCardiology and Cardiovascular MedicineClaudicationbusinessmedicine.drugCardiovascular drugs and therapy
researchProduct

Changes in myocardial iron content following administration of intravenous iron (Myocardial‐IRON): Study design

2018

Treatment with intravenous ferric carboxymaltose (FCM) has been shown to improve symptoms, functional capacity, and quality of life in patients with heart failure and iron deficiency. However, the underlying mechanisms for these beneficial effects remain undetermined. The aim of this study is to quantify cardiac magnetic resonance changes in myocardial iron content after administration of intravenous FCM in patients with heart failure and iron deficiency and contrast them with parameters of heart failure severity. This is a multicenter, double-blind, randomized study. Fifty patients with stable symptomatic heart failure, left ventricular ejection fraction <50%, and iron deficiency will be r…

MaleTime FactorsMyocardial ironheart failure030204 cardiovascular system & hematologyFerric CompoundsSeverity of Illness IndexVentricular Function Left030218 nuclear medicine & medical imaginglaw.invention0302 clinical medicineiron deficiencyClinical ProtocolsQuality of lifeRandomized controlled triallawCardiac Magnetic Resonance Ferric Carboxymaltose Heart Failure Iron Deficiency Myocardial IronInfusions IntravenousEjection fractionAnemia Iron-DeficiencyGeneral MedicineIron deficiencyferric carboxymaltoseTreatment OutcomeResearch DesignCardiologyFemaleCardiology and Cardiovascular MedicineCardiac function curvemedicine.medical_specialtyTrial DesignsMagnetic Resonance Imaging CinePlacebocardiac magnetic resonance03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansMaltosemyocardial ironAgedHeart Failurebusiness.industryMyocardiumStroke VolumeRecovery of Functionmedicine.diseaseSpainHeart failureHematinicsQuality of Lifebusiness
researchProduct

Modulation of Spatial O2Tension Distribution in Experimental Tumors by Increasing Arterial O2Supply

1995

Tumor oxygenation has been measured polarographically in s.c. implanted DS-sarcomas on the dorsum of the hind foot of male Sprague-Dawley rats. pO2 was determined in all 3 spatial dimensions and 3-dimensional pO2 distributions as well as the mean extent of confluent areas with pO25 mmHg were calculated. Finally, the effect of elevating arterial pO2 (by carbogen breathing) as well as of increasing tumor blood flow (by angiotensin infusion) on the spatial pO2 distribution was analyzed. Depending on the tumor volume, the spatial pO2 distribution is more or less anisotropic. In smaller tumors, areas with physiological pO2 values are found adjacent to large hypoxic areas whereas larger tumors ar…

Maleinorganic chemicalsRadiation-Sensitizing Agentsmedicine.medical_specialtyPartial PressureRats Sprague-DawleyOxygen ConsumptionInternal medicineRenin–angiotensin systemmedicineAnimalsRadiology Nuclear Medicine and imagingInfusions IntravenousSmall tumorsTissue po2business.industryAngiotensin IIArteriesHematologyGeneral MedicineBlood flowCarbon Dioxiderespiratory systemTumor OxygenationRatsOxygenbody regionsOncologyRegional Blood FlowAnesthesiaArterial pO2cardiovascular systemCardiologyCarbogen BreathingSarcoma Experimentalmedicine.symptombusinessVasoconstrictionPolarographycirculatory and respiratory physiologyActa Oncologica
researchProduct